US Pharma MarketingOdyssey raises more than $300M as biotech goes public in IPO
Odyssey Therapeutics raised $279 million in an upsized IPO priced at $18 a share, with the autoimmune disease biotech set to begin Nasdaq trading Friday. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene…
Odyssey Therapeutics pulled together $279 million from its initial public offering, the autoimmune disease drug developer said Thursday night.
With its IPO now priced, Odyssey is slated to begin trading on the Nasdaq on Friday ...
Source: Endpoints News